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Background: The management of Medication overuse headache (MOH) represents a difficult challenge for clinicians
and headache experts, particularly for the responder rate after a successful withdrawal treatment. The purpose of this
study was to investigate the role of demographic and clinical characteristics as well as the score of Migraine-Specific
Quality of Life Questionnaire (MSQ), Migraine Disability Questionnaire and Leeds Dependence Questionnaire in
predicting a response after a successful withdrawal treatment in patients with MOH.
Methods: This ancillary study is part of a randomized trial that demonstrated the safety and the efficacy of a
3-month treatment with sodium valproate (VPA) (800 mg/day vs placebo) in MOH. Demographic and clinical
characteristics and questionnaire results were obtained from the entire sample.
Results: A significant correlation was found only between MOH relapse and the total MSQ score, the Role
Preventive sub-scale and the Emotional Function sub-scale, suggesting a poorer quality of life in non responders.
Conclusion: A high MSQ score could be associated with a poor short-term outcome in MOH patients after a successful
treatment with detoxification followed by a new treatment.
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Medication-overuse headache (MOH) is a chronic head-
ache having a relevant impact in clinical practice, with a
prevalence of 1-2 % in the general population [1, 2]. The
primary headache leading to MOH is migraine in most
cases. The management of MOH represents a difficult
challenge for clinicians and headache experts [3]. Indeed,
even in case of a successful withdrawal treatment, the
relapse rate of MOH ranges between 24 % and 43 %
(40 % during the first year after withdrawal) [4]. Most
studies indicate that the relapse usually occurs within
few months after detoxification [5].
In recent years an increasing number of studies focused
on the predictors of relapse of MOH, but no reproducible
results have been achieved. While in a 4-year follow-up no
significant predictors were found [6], in three studies with
1-year follow-up, predictors of relapse were, respectively, a* Correspondence: paola.sarchielli@gmail.com
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higher frequency of migraine after withdrawal, and a great
number of previous preventive treatments [7], male sex,
intake of combination analgesics after withdrawal, nicotine
and alcohol consumption [8], the type of primary headache
and the type of the overused medication [9]. Generally,
even if proper instructions and appropriate surveillance
are considered necessary to avoid relapse [4], no definite
clinical predictors for the management of MOH patients
are available.
The complexity ofMOH often depends on the comor-
bidities that are reported more frequently compared to
what happens for episodic headaches. Thus, MOH pa-
tients show increased disability, reduced mood and social
impairment compared with episodic migraineurs, leading
to a worsening in their quality of life [3]. Recently, a high
score measured by a self-reported quality of life tool re-
sulted a predictor for a poor outcome of MOH patients
[10]. In the last years patient-reported outcome measures
have been applied to MOH to evaluate the consequence
of this disorder on patients’ daily lives. Therefore, asarticle distributed under the terms of the Creative Commons Attribution License
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scores could be considered as secondary endpoints in clin-
ical trials along with clinical characteristics of MOH.
Moreover, they could be investigated as outcome and
relapse predictors.
Recently, the Sodium vAlproate in the treatment of
Medication Overuse HeadAche (SAMOHA) study dem-
onstrated the efficacy and safety of sodium valproate
(VPA), after detoxification, in the short-term treatment of
MOH patients with a history of migraine without aura.
Moreover, patients treated with VPA reported a signifi-
cantly higher improvement in the MSQ at the end of the
treatment, compared to controls, whereas this difference
was non-significant at the 3-month follow-up visit [11]. In
light of this, we analysed data obtained from patients en-
rolled in the SAMOHA study, in order to investigate the
role of the basal demographic and clinical characteristics
along with disability, dependence and quality of life as out-
come and response predictors.
Methods
Standard protocol approvals, registrations, and patient
consents
As an ancillary study, the protocol was submitted for ap-
proval to the Ethics Committees of each participating cen-
ter. The SAMOHA trial was registered on the European
Union Drug Regulating Authorities Clinical Trials web-
site (EudraCT code 2007-006773-92; https://www.clinical
trialsregister.eu/ctr-search/trial/2007-006773-92/IT). The
SAMOHA study was conducted in accordance with the
Declaration of Helsinki and its amendments (Seoul, October
2008). All patients provided their written consent to partici-
pate in the study.
Subjects
The SAMOHA study was a multicenter, randomized,
double-blind, placebo-controlled study that randomized 88
MOH patients for a 3-month treatment period with VPA
(800 mg/day) or placebo after a 6-day outpatient detoxifi-
cation regimen, followed by a 3-month follow-up [12].
Statistical analysis
This report describes post-hoc secondary data analysis
from the SAMOHA study. Analyses were performed in
the intent-to-treat population. Missing data were han-
dled using the last observation carried forward approach
(LOCF) in patients with at least one assessment. Demo-
graphic (sex, age), clinical (body mass index, comorbid-
ity, surgery) and headache characteristics (frequency,
intensity, total and MOH duration, overused drugs), the
Migraine Specific Quality of Life Questionnaire (MSQ)
[12] score, and the scores of the three sub-scales– Role
Restriction (RR), Role Preventive (RP) and Emotional
Function (EF), − as well as the Migraine DisAbilityqueStionnaire (MIDAS) [13] and the Leeds Dependence
Questionnaire (LDQ) [14] scores, were compared at
baseline in Responders (patients achieving ≥50 % re-
duction in the number of days with headache per
month) and Non-Responders at the 24-week visit (R and
NR, respectively). Comparisons between R and NR are re-
ported as count and percentage, or median and interquar-
tile range (IQR). Differences between the two groups were
tested using the Fisher’s exact test or the Wilcoxon-
Mann–Whitney test. Data resulting significant in univari-
ate analysis were also adjusted for treatment using logistic
regression models. Results are reported as adjusted odds
ratios (OR) with 95 % confidence intervals (CI). All tests
were two-tailed, and the significance level was set at 5 %.
All analyses were performed using the SAS statistical ana-
lysis system version 9.2 (SAS Institute Inc., Cary, NC,
USA).
Results
The LOCF imputation method allowed the identification
of 31 R and 51 NR at 24 weeks (3 months after the dis-
continuation of treatment). The 3-month proportion of
patients achieving ≥50 % reduction in the number of
days with headache per month in the entire sample was
34.1 %, while this rate was 37.8 % at the 24-week visit. A
significant difference between R and NR was found for
the total MSQ score (median 33.0, IQR 24.0-41.0, vs.
40.0, IQR 27.0-50.0, p = 0.0180), the RP sub-scale (me-
dian 6.0, IQR 5.0-9.0, vs. 9.0, IQR 6.0-13.0, p = 0.0195)
and the EF sub-scale (median 5.0, IQR 2.0-7.0, vs. 8.0,
IQR 4.0-12.0), while the RR sub-score and the total
MIDAS and LDQ total scores as well as the other demo-
graphic, clinical and headache variables were evenly dis-
tributed in the two groups (Table 1). After adjusting for
treatment, the association between MOH relapse and the
total MSQ, the RP sub-scale and the EF sub-scale, was still
statistically significant. The adjusted ORs were: 1.04 (95 %
CI 1.01 – 1.08, p = 0.0249) for the total MSQ, 1.15 (95 %
CI 1.03 – 1.29, p = 0.0163) for the RP sub-scale, and 1.14
(95 % CI 1.02 – 1.28, p = 0.0257) for the EF sub-scale.
Discussion
Our findings suggest that only a high MSQ score is asso-
ciated with a poor short-term outcome after a successful
treatment with detoxification followed by a new treat-
ment. In particular, the most significant difference was
found for the RP and EF sub-scales, that measure the de-
gree to which performance of normal activities is prevented
or completely interrupted by headache and, respectively,
the impact of symptoms on emotional well-being. These
aspects can be considered the very disabling aspects of
headache compared to those measured by the RR sub-
scale. The MSQ score can be considered an indicator of
headache severity self-reported by the patients, assessing
Table 1 Comparison of baseline demographic, clinical and headache characteristics, total MSQ, EF, RP and RR, MIDAS and LDQ,
between responders and non-responders at the 24-week visit
Non-responders (51) Responders (31)
n (%) n (%) p-value
Sex
F 41 (80.4) 24 (77.4) 0.7475
M 10 (19.6) 7 (22.58)
Age class (years)
18-34 years 8 (15.7) 5 (16.1) 0.6547
35 - 44 years 20 (39.2) 10 (32.3)
45 - 54 years 18 (35.3) 10 (32.3)
55 - 64 years 5 (9.8) 6 (19.3)
BMI class
(<18) Underweight 2 (4) 1 (3.2) 0.4466
(18–24.9) Normalweight 32 (64) 17 (54.8)
(25–29.9) Overweight 10 (20) 11 (35.5)
(>30) Obese 6 (12) 2 (6.5)
Missing 1
Comorbidity
No 36 (70.6) 25 (80.7) 0.3117
Yes 15 (29.4) 6 (19.3)
Surgery
No 15 (30.6) 7 (23.3) 0.4836
Yes 34 (69.4) 23 (76.7)
Missing 2 1
Headache days/month
15-25 22 (43.1) 17 (54.8) 0.3036
>25 29 (56.9) 14 (45.2)
Headache intensity
Slight 0 (0) 3 (9.7) 0.0639
Moderate 20 (39.2) 9 (29)
Severe 31 (60.8) 19 (61.3)
Headache duration (years)
0 - 10 years 8 (15.7) 3 (9.7) 0.8787
11 - 20 years 12 (23.5) 7 (22.6)
21 - 30 years 16 (31.4) 11 (35.5)
>30 years 15 (29.4) 10 (32.2)
MOH duration (years)
<1 year 7 (13.7) 3 (9.7) 0.6263
1-3 years 13 (25.5) 11 (35.5)
3-5 years 13 (25.5) 5 (16.1)
>5 years 18 (35.3) 12 (38.7)
Over used drugs
Analgesics > 14 days 20 (39.2) 9 (29) 0.3617
Analgesicscombinations > 9 days 5 (9.8) 7 (22.6)
Drugcombinations > 9 days 15 (29.4) 7 (22.6)
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Table 1 Comparison of baseline demographic, clinical and headache characteristics, total MSQ, EF, RP and RR, MIDAS and LDQ,
between responders and non-responders at the 24-week visit (Continued)
Triptancombinations > 9 days 11 (21.6) 8 (25.8)
Median (IQR) Median (IQR) p-value
MSQ 40.0 (27.0 - 50.0) 33.0 (24.0 - 41.0) 0.0180
EF 8.0 (4.0 - 12.0) 5.0 (2.0 - 7.0) 0.0330
RP 9.0 (6.0 - 13.0) 6.0 (5.0 - 9.0) 0.0195
RR 23.0 (16.0 - 27.0) 18.0 (15.0 - 24.0) 0.1188
MIDAS 70 (24.0 - 96.0) 38.0 (15.0 - 75.0) 0.1119
LDQ 7.0 (5.0 - 14.0) 8.0 (7.0 - 13.0) 0.5031
BMI: Body Mass Index




MIDAS: MIgraine DisAbility queStionnaire
LDQ: Leeds Dependence Questionnaire
IQR: Interquartile range
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MOH patients reporting a high MSQ score before treat-
ment should be considered at high risk of short-term
treatment failure. This result can be of substantial help for
clinicians in the management of this type of headache. Of
note, the lack of correlation between response and the
MIDAS and the LDQ scores indicates that quality of life
rather than functional disability and dependence is likely
to have an influence on the response to any new treatment
in patients with MOH.
All the other variables were evenly distributed in the
two groups. These findings are in contrast with previous
studies [6–9], perhaps because of the high variability
among study populations. Further main reasons for non-
reproducible results are probably differences in protocol,
treatment and follow-up.
On this background, our results can represent a useful
starting point for the general management of MOH. In
fact, it is possible to argue that if a high MSQ score is
reported, even in absence of relevant comorbidities, the
patient should be considered at high risk of short-term
treatment failure. Moreover, MSQ is easy to obtain,
patient-friendly, reproducible, and suitable for short- and
long-term follow-up.
Our study has some limitations. First, the small sample
size prevents definitive results on the demographic and
clinical characteristics we investigated. Second, our study
analyzed a short-term follow-up, thus the correlation be-
tween MSQ score and response to treatment in the long-
term was not assessed. Third, as we did not adjust for
multiple comparisons, the possibility that our results are
chance findings cannot be excluded. A prospective study
is thus needed to compare MSQ with the clinical charac-
teristics of patients suffering from MOH (including thetreatment protocols) to predict short- and long-term spe-
cific outcomes.
Conclusions
In conclusion, our findings suggest that a high MSQ score
may be associated to a negative outcome of MOH patients
after detoxification followed by a new treatment. Larger
studies with longer follow-up are needed to clarify this
issue given that their results could lead to a better man-
agement of MOH patients.
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